NeuBase Therapeutics (NBSE) 10-Q2013 Q1 Quarterly report

Filed: 19 Feb 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: academic, adjusted, agreement, AMD, Andrew, approxiamately, bank, blind, broadband, brought, cancelled, case, categorization, cessation, classification, complaint, corroborated, credit, defend, defendant, description, discretion, disposing, double, enterprise, equivalent, extend, extension, fewer, fixed, forum, fourth, goodwill, hierarchy, identical, impact, inhibitor, input, intrinsic, joint, key, laboratory, lawsuit, line, lowest, manufacturing, maritime, maturity, merged, merit, methodology, million, outcome, primary, publish, quoted, randomized, readily, receptionist, recievable, Reconciliation, reliant, rescue, residual, retired, scheduled, secondary, sheet, shell, space, storage, successor, supplier, survival, surviving, treated, twenty, unadjusted, Unamortized, uncertain, Utah, vary, venture, vigorously, warranty

Removed: ability, accomplish, accomplishing, accumulated, adversely, Advisor, afforded, amortized, amounting, anterior, attain, average, Benchmark, bifurcated, borrowing, cease, chamber, charge, combined, condensed, confirming, consisting, contact, core, cornea, cover, debt, deficit, dependent, developing, discontinue, dividend, doubt, entity, estimated, eventually, exchanged, exist, expensed, finalized, Floor, forced, forfeited, free, fund, hiring, holder, humor, implement, indexed, inducement, initiative, insufficient, item, joined, leaving, legal, licensure, liquidation, lower, maintain, mentioned, minimal, moving, note, obliged, obtain, order, outlay, paragraph, passing, pay, paying, payment, pending, penetrate, plan, preceding, predecessor, predetermined, prepaid, pricing, product, profitable, projected, protect, protection, ratchet, realization, recognize, reflected, rely, revaluation, revalued, salary, secure, shifted, sooner, stabilized, statement, strike, subsequently, subsidiary, successfully, suggested, support, team, technology, test, threatened, Topic, trading, unable, undercapitalized, undetectable, view, volatility, whichever, yield, York

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NBSE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Ohr Pharmaceutical, Inc. 10-Q

Exhibit 32.1

Certification of Chief Executive Officer

Pursuant to 18 U.S.C Section 1350,

As Adopted Pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

Not Filed Pursuant to the Securities Exchange Act of 1934

In connection with the Quarterly Report of Ohr Pharmaceutical, Inc. (the “Company” ) on Form 10-Q for the period ending June 30, 2012 as filed with the Securities and Exchange Commission on the date hereof the “Report” ), I, Irach Taraporewala , Chief Executive Officer, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	1.	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 19, 2013

/s/ Irach Taraporewala
Name: Irach Taraporewala
Title: Chief Executive Officer